Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13713687 | 0.84 | FYN (0.52) | FYN | |
| SCHEMBL12674822 | 0.80 | KDM4E (0.50) | FYNKDM1AMAOAMAOB | |
| SCHEMBL12674838 | 0.79 | CYP3A4 (0.39) | FYN | |
| SCHEMBL12675292 | 0.78 | MEN1 (0.49) | FYNADORA2AADORA2BCYP2C9CYP2C19 | |
| SCHEMBL12674820 | 0.78 | KDR (0.39) | FYNADORA2AKDM1AMAOAMAOB | |
| SCHEMBL12675335 | 0.77 | ADORA2A (0.41) | ADORA2AKDM1AMAOAMAOBCYP2C9 | |
| SCHEMBL1884545 | 0.77 | CYP2C9 (0.50) | ADORA2AADORA2BKDM1AMAOAMAOB | |
| SCHEMBL12675345 | 0.77 | CYP3A4 (0.42) | FYNCHRM4 | |
| SCHEMBL2599916 | 0.74 | KMT2A (0.44) | ADORA2AKDM1AMAOAMAOBCYP2C9 | |
| SCHEMBL12675349 | 0.72 | HTR2A (0.41) | FYNKDM1AMAOAMAOBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | FYN 8/4885ADORA2A 2539/4885ADORA2B 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.